Activation of coagulation and inhibition of fibrinolysis in the human lung on bronchial instillation of lipoteichoic acid and lipopolysaccharide

Critical Care Medicine

Volumn 37, Issue 2, 2009, Pages 619-625

  Hoogerwerf, Jacobien J ^a   De Vos, Alex F ^a   Levi, Marcel ^a   Bresser, Paul ^a   Van Der Zee, Jaring S ^a   Draing, Christian ^b   Von Aulock, Sonja ^b   Van Der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

Coagulation; Fibrinolysis; Human lung; Inflammation; Lipopolysaccharide; Lipoteichoic acid

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; D DIMER; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; LIPOTEICHOIC ACID; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; SODIUM CHLORIDE; THROMBIN ANTITHROMBIN COMPLEX; THROMBOMODULIN; THROMBOPLASTIN;

ADULT; ANTICOAGULATION; ARTICLE; BACTERIAL PNEUMONIA; BLOOD CLOTTING; BRONCHUS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG INSTILLATION; ESCHERICHIA COLI; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; INHIBITION KINETICS; LUNG; LUNG LAVAGE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STAPHYLOCOCCUS AUREUS;

BLOOD COAGULATION; BRONCHI; BRONCHOALVEOLAR LAVAGE FLUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYSIS; HEMOSTASIS; HUMANS; LIPOPOLYSACCHARIDES; LUNG; MALE; TEICHOIC ACIDS; THROMBOPLASTIN; YOUNG ADULT;

EID: 67650379781     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31819584f9     Document Type: Article

References (45)

1. Gunther A, Mosavi P, Heinemann S, et al: Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 161: 454-462
2. Ware LB, Fang X, Matthay MA: Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003; 285:L514-L521
3. Rijneveld AW, Florquin S, Bresser P, et al: Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia. Blood 2003; 102:934-939
4. Rijneveld AW, Weijer S, Bresser P, et al: Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia. Crit Care Med 2006; 34:1725-1730
5. Choi G, Schultz MJ, van Till JW, et al: Disturbed alveolar fibrin turnover during pneumonia is restricted to the site of infection. Eur Respir J 2004; 24:786-789
6. Choi G, Schultz MJ, Levi M, et al: Protein C in pneumonia. Thorax 2005; 60:705-706
7. El Solh AA, Choi G, Schultz MJ, et al: Clinical and hemostatic responses to treatment in ventilator-associated pneumonia: Role of bacterial pathogens. Crit Care Med 2007; 35: 490-496
8. Schultz MJ, Millo J, Levi M, et al: Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax 2004; 59: 130-135
9. Opal SM: Phylogenetic and functional relationships between coagulation and the innate immune response. Crit Care Med 2000; 28:S77-S80
10. Levi M, Schultz MJ, Rijneveld AW, et al: Bronchoalveolar coagulation and fibrinolysis in endotoxemia and pneumonia. Crit Care Med 2003; 31:S238-S242
11. Maris NA, de Vos AF, Bresser P, et al: Salmeterol enhances pulmonary fibrinolysis in healthy volunteers. Crit Care Med 2007; 35: 57-63
12. Maris NA, de Vos AF, Bresser P, et al: Activation of coagulation and inhibition of fibrinolysis in the lung after inhalation of lipopolysaccharide by healthy volunteers. Thromb Haemost 2005; 93:1036-1040
13. van der Poll T, Levi M, Nick JA, et al: Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am J Respir Crit Care Med 2005; 171:1125-1128
14. Suffredini AF, Harpel PC, Parrillo JE: Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320:1165-1172
15. van der Poll T, Coyle SM, Levi M, et al: Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood 1997; 89:3727-3734
16. de Jonge E, Dekkers PE, Creasey AA, et al: Tissue factor pathway inhibitor dose-depen-dently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000; 95:1124-1129
17. Derhaschnig U, Reiter R, Knobl P, et al: Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. Blood 2003; 102: 2093-2098
18. Beutler B, Jiang Z, Georgel P, et al: Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu Rev Immunol 2006; 24:353-389
19. Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell 2006; 124:783-801
20. Choi G, Hofstra JJ, Roelofs JJ, et al: Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats. Crit Care Med 2007; 35:1362-1368
21. Choi G, Hofstra JJ, Roelofs JJ, et al: Anti-thrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats. Crit Care Med 2008; 36:204-210
22. Dessing MC, Schouten M, Draing C, et al: Role played by Toll-like receptors 2 and 4 in lipoteichoic acid-induced lung inflammation and coagulation. J Infect Dis 2008; 197: 245-252
23. Hoogerwerf JJ, de Vos AF, Bresser P, et al: Lung inflammation induced by lipoteichoic acid or lipopolysaccharide in humans. Am J Respir Crit Care Med 2008; 178:34-41
24. Morath S, Geyer A, Hartung T: Structure-function relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus. J Exp Med 2001; 193:393-397
25. Morath S, Geyer A, Spreitzer I, et al: Structural decomposition and heterogeneity of commercial lipoteichoic acid preparations. Infect Immun 2002; 70:938-944
26. O'Grady NP, Preas HL, Pugin J, et al: Local inflammatory responses following bronchial endotoxin instillation in humans. Am J Respir Crit Care Med 2001; 163:1591-1598
27. Nick JA, Coldren CD, Geraci MW, et al: Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004; 104:3878-3885
28. Levi M, de Boer JP, Roem D, et al: Plasminogen activation in vivo upon intravenous infusion of DDAVP. Quantitative assessment of plasmin-alpha 2-antiplasmin complex with a novel monoclonal antibody based radioim-munoassay. Thromb Haemost 1992; 67: 111-116
29. ten Cate H, Lamping RJ, Henny CP, et al: Automated amidolytic method for determining heparin, a heparinoid, and a low-Mr heparin fragment, based on their anti-Xa activity. Clin Chem 1984; 30:860-864
30. Verheijen JH, Mullaart E, Chang GT, et al: A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemost 1982; 48:266-269
31. Liaw PC, Ferrell G, Esmon CT: A monoclonal antibody against activated protein C allows rapid detection of activated protein C in plasma and reveals a calcium ion dependent epitope involved in factor Va inactivation. J Thromb Haemost 2003; 1:662-670
32. Levi M, van der Poll T: Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med 2005; 15:254-259
33. Miller DL, Welty-Wolf K, Carraway MS, et al: Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. Am J Respir Cell Mol Biol 2002; 26: 650-658
34. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
35. Wheeler AP, Bernard GR: Treating patients with severe sepsis. N Engl J Med 1999; 340: 207-214
36. Malley R, Henneke P, Morse SC, et al: Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci USA 2003; 100: 1966-1971
37. Gutberlet T, Frank J, Bradaczek H, et al: Effect of lipoteichoic acid on thermotropic membrane properties. J Bacteriol 1997; 179: 2879-2883
38. Cross AS, Opal SM, Sadoff JC, et al: Choice of bacteria in animal models of sepsis. Infect Immun 1993; 61:2741-2747
39. Draing C, Sigel S, Deininger S, et al: Cytokine induction by Gram-positive bacteria. Immunobiology 2008; 213:285-296
40. Drake TA, Morrissey JH, Edgington TS: Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134:1087-1097
41. Wygrecka M, Markart P, Ruppert C, et al: Compartment- and cell-specific expression of coagulation and fibrinolysis factors in the murine lung undergoing inhalational versus intravenous endotoxin application. Thromb Haemost 2004; 92:529-540
42. Hataji O, Taguchi O, Gabazza EC, et al: Activation of protein C pathway in the airways. Lung 2002; 180:47-59
43. Rijneveld AW, Weijer S, Florquin S, et al: Thrombomodulin mutant mice with a strongly reduced capacity to generate activated protein C have an unaltered pulmonary immune response to respiratory pathogens and lipopolysaccharide. Blood 2004; 103: 1702-1709
44. Alcaraz A, Espana F, Sanchez-Cuenca J, et al: Activation of the protein C pathway in acute sepsis. Thromb Res 1995; 79:83-93
45. Eckle I, Seitz R, Egbring R, et al: Protein C degradation in vitro by neutrophil elastase. Biol Chem Hoppe Seyler 1991; 372: 1007-1013